Correction to: CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation (Cell Death & Differentiation, (2013), 20, 3, (443-455), 10.1038/cdd.2012.136);CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation

Cell Death and Differentiation

Volumn 20, Issue 3, 2013, Pages 443-455

  Chang, C C ^a   Yang, M H ^b,c   Lin, B R ^a   Chen, S T ^a   Pan, S H ^d   Hsiao, M ^e   Lai, T C ^e   Lin, S K ^a   Jeng, Y M ^a   Chu, C Y ^a   Chen, R H ^f   Yang, P C ^d,g   Eugene Chin, Y ^h   Kuo, M L ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e GENOMICS RESEARCH CENTER   (Taiwan)

^f INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^g INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^h BROWN UNIVERSITY   (United States)

Author keywords

anoikis; CCN2; EGFR; metastasis

Indexed keywords

CBL PROTEIN; CETUXIMAB; CONNECTIVE TISSUE GROWTH FACTOR; DEATH ASSOCIATED PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE INTERACTING EXCHANGE FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANOIKIS; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG CANCER; METASTASIS INHIBITION; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

EID: 84873709117     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/s41418-018-0140-5     Document Type: Erratum

References (36)

1. Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003; 63: 1-5.
2. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009; 218: 460-466.
3. Liotta LA, Kohn E. Anoikis: cancer and the homeless cell. Nature 2004; 430: 973-974.
4. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E. Peeper DS Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004; 430: 1034-1039.
5. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007; 369: 1742-1757.
6. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007; 213: 316-325.
7. Geiger TR, Peeper DS. Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res 2007; 67: 6221-6229.
8. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003; 5: 733-740.
9. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009; 41: 771-783.
10. Luft FC. CCN2, the connective tissue growth factor. J Mol Med 2008; 86: 1-3.
11. Chu CY, Chang CC, Prakash E, Kuo ML. Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci 2008; 15: 675-685.
12. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-549.
13. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004; 10: 2072-2081.
14. Koliopanos A, Friess H, di Mola FF, Tang WH, Kubulus D, Brigstock D et al. Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 2002; 26: 420-427.
15. Liu L, Li Z, Feng G, You W, Li J. Expression of connective tissue growth factor is in agreement with the expression of VEGF, VEGF-C, -D and associated with shorter survival in gastric cancer. Pathol Int 2007; 57: 712-718.
16. Zeng ZJ, Yang LY, Ding X, Wang W. Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance. World J Gastroenterol 2004; 10: 3414-3418.
17. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, Yang CY et al. Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology 2005; 128: 9-23.
18. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, Chen ST et al. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 2004; 96: 364-375.
19. Chang CC, Lin MT, Lin BR, Jeng YM, Chen ST, Chu CY et al. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. J Natl Cancer Inst 2006; 98: 984-995.
20. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775-787.
21. Schmiedel J, Blaukat A, Li S, Kno chel T, Ferguson KM. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 2008; 13: 365-373.
22. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6: 587-595.
23. Muthuswamy SK, Muller WJ. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene 1995; 11: 271-279.
24. Padron D, Sato M, Shay JW, Gazdar AF, Minna JD, Roth MG. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. Cancer Res 2007; 67: 7695-7702.
25. Pennock S, Wang Z. A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation. Mol Cell Biol 2008; 28: 3020-3037.
26. Umebayashi K, Stenmark H, Yoshimori T. Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation. Mol Biol Cell 2008; 19: 3454-3462.
27. Wu WJ, Tu S, Cerione RA. Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell 2003; 114: 715-725.
28. Feng Q, Baird D, Peng X, Wang J, Ly T, Guan JL et al. Cool-1 functions as an essential regulatory node for EGF receptor- and Src-mediated cell growth. Nat Cell Biol 2006; 8: 945-956.
29. Yamaguchi H, Woods NT, Dorsey JF, Takahashi Y, Gjertsen NR, Yeatman T et al. SRC directly phosphorylates Bif-1 and prevents its interaction with Bax and the initiation of anoikis. J Biol Chem 2008; 283: 19112-19118.
30. Hara K, Senga T, Biswas MH, Hasegawa H, Ito S, Hyodo T et al. Recovery of anoikis in Src-transformed cells and human breast carcinoma cells by restoration of the SIRP{alpha}1/SHP-2 signaling system. Cancer Res 2011; 71: 1229-1234.
31. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T et al. PID: the pathway interaction database. Nucleic Acids Res 2009; 37: D674-D679.
32. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390: 180-184.
33. Chen RH, Wang WJ, Kuo JC. The tumor suppressor DAP-kinase links cell adhesion and cytoskeleton reorganization to cell death regulation. J Biomed Sci 2006; 13: 193-199.
34. Singh AB, Harris RC. Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells. J Biol Chem 2004; 279: 3543-3552.
35. Sorokin A, Lemmon MA, Ullrich A, Schlessinger J. Stabilization of an active dimeric form of the epidermal growth factor receptor by introduction of an inter-receptor disulfide bond. J Biol Chem 1994; 269: 9752-9759.
36. Wang WJ, Kuo JC, Ku W, Lee YR, Lin FC, Chang YL et al. The tumor suppressor DAPK is reciprocally regulated by tyrosine kinase Src and phosphatase LAR. Mol Cell 2007; 27: 701-716.